featured
2020 Top Stories in Advanced Prostate Cancer: Olaparib and Rucaparib FDA Approvals
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091-2102.
- Hussain M, Mateo J, Fizazi K, et al; PROfound Trial Investigators. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020 Sep 20. doi:10.1056/NEJMoa2022485. Online ahead of print.
- Abida W, Patnaik A, Campbell C, et al; on behalf of the TRITON2 investigators. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1or BRCA2 gene alteration. J Clin Oncol. 2020;38(32)3763-3772.
- FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. News release. May 30, 2017. Accessed November 20, 2020.
- FDA approves pembrolizumab for adults and children with TMB-H solid tumors. News release. June 17, 2020. Accessed November 20, 2020.
Disclosure statements are available on the authors' profiles:
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.